Stem cell therapy for chronic obstructive pulmonary disease
Part of Lungs & breathing clinical trials.
This trial tests whether a special stem cell treatment can help people with moderate to severe COPD when regular medicines are not working well. The treatment may reduce breathing problems and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have a diagnosis of moderate to severe COPD (GOLD grades 2–4).
- You have been using COPD medications regularly for at least 3 months and your condition has been stable for over a month.
- You have not smoked for at least 6 months before the trial, and you agree not to smoke during the trial.
- You do not have other serious lung diseases like asthma, tuberculosis, or interstitial lung disease.
- You have not had lung surgery or a recent COPD flare-up in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding umbilical cord stem cells to standard triple therapy can help people with Group E COPD. It aims to see if this approach improves lung function and quality of life.
This trial tests whether transplanting a patient's own lung stem cells can improve lung function in people with chronic obstructive pulmonary disease (COPD). It aims to see if this treatment is safe and helps repair damaged lung tissue.
This trial is testing a new type of cell therapy called REGEND007 for people with COPD. It looks at whether the treatment can help improve how far you can walk and your overall breathing.
This trial is testing an experimental treatment using special cells called clonal fetal mesenchymal stem cells (cfMSCs) to help control overactive immune responses. The goal is to reduce symptoms of immune disorders like graft-versus-host disease (GVHD) when other treatments have not worked.
This phase 3 trial tests a new cell-based treatment (REGEND001) for people with moderate to severe COPD, especially those with emphysema. The treatment aims to repair damaged lung tissue, potentially improving breathing and quality of life.
This study tests a new treatment made from small mobile stem cells, given by inhalation, for people with moderate to severe COPD caused by smoking or pollution. It aims to see if the treatment is safe and helps improve lung function.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.